Eric D. Hostetler
YOU?
Author Swipe
View article: The Novel PET Radioligand [ <sup>11</sup> C]MK‐7337 Detects Alpha‐Synuclein Pathology in Parkinson's Disease Patients
The Novel PET Radioligand [ <sup>11</sup> C]MK‐7337 Detects Alpha‐Synuclein Pathology in Parkinson's Disease Patients Open
Background To date, clinical feasibility of imaging Lewy‐body pathology and related disease progression in Parkinson's disease (PD) patients remains unclear. Supported by the Michael J. Fox Foundation through Ken Griffin Alpha‐Synuclein (A…
View article: External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units Open
Background The Joint Propagation Model (JPM)‐based CenTauR scale was recently introduced to harmonize tau‐PET quantification across different radiotracers. This study examined how CenTauR harmonization enhances the comparability of tau‐PET…
View article: Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model Open
INTRODUCTION Tau‐positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer properties, instr…
View article: Progress in imaging by α‐synuclein Positron Emission Tomography
Progress in imaging by α‐synuclein Positron Emission Tomography Open
Background Deposition of misfolded α‐synuclein (α‐Syn) aggregates in the human brain is one of the major hallmarks of synucleinopathies. Positron Emission Tomography imaging (PET) of α‐synuclein in Parkinson’s disease (PD) patients is high…
View article: Estimating Braak stage from [<sup>18</sup>F]MK6240 PET scans
Estimating Braak stage from [<sup>18</sup>F]MK6240 PET scans Open
Background [ 18 F]MK6240 is a second‐generation radiotracer for imaging tau pathology in vivo. Regional thresholds that allow for an assessment of Braak stage have yet to be established and importantly may vary between regions. In this wor…
View article: Harmonization of tau‐PET in Alzheimer’s disease: comparison of methods to derive CenTauR units for [18F]RO948, [18F]Flortaucipir, and [18F]MK‐6240
Harmonization of tau‐PET in Alzheimer’s disease: comparison of methods to derive CenTauR units for [18F]RO948, [18F]Flortaucipir, and [18F]MK‐6240 Open
Background Tau positron emission tomography (PET) is increasingly used in the clinical evaluation of patients and as an outcome measure in Alzheimer’s disease (AD) clinical trials. Due to differences in tracer properties, instrumentation, …
View article: Harmonization of tau‐PET in Alzheimer’s disease: comparison of methods to derive CenTauR units for [<sup>18</sup>F]RO948, [<sup>18</sup>F]Flortaucipir, and [<sup>18</sup>F]MK‐6240
Harmonization of tau‐PET in Alzheimer’s disease: comparison of methods to derive CenTauR units for [<sup>18</sup>F]RO948, [<sup>18</sup>F]Flortaucipir, and [<sup>18</sup>F]MK‐6240 Open
Background Tau positron emission tomography (PET) is increasingly used in the clinical evaluation of patients and as an outcome measure in Alzheimer’s disease (AD) clinical trials. Due to differences in tracer properties, instrumentation, …
View article: Discovery of [<sup>11</sup>C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR<sub>2</sub> Negative Allosteric Modulators
Discovery of [<sup>11</sup>C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR<sub>2</sub> Negative Allosteric Modulators Open
Modification of potent, selective metabotropic glutamate receptor 2 negative allosteric modulator (mGluR2 NAM) led to a series of analogues with excellent binding affinity, lipophilicity, and suitable physicochemical properties for a PET t…
View article: MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy
MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy Open
Deposition of hyperphosphorylated and aggregated tau protein in the central nervous system is characteristic of Alzheimer disease and other tauopathies. Tau is subject to O-linked N-acetylglucosamine (O-GlcNAc) modification, and O-GlcNAcyl…
View article: Discovery of [<sup>11</sup>C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases
Discovery of [<sup>11</sup>C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases Open
The measurement of receptor occupancy (RO) using positron emission tomography (PET) has been instrumental in guiding discovery and development of CNS directed therapeutics. We and others have investigated muscarinic acetylcholine receptor …
View article: Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor
Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor Open
A growing body of evidence has implicated the calcitonin gene-related peptide (CGRP) receptors in migraine pathophysiology. With the recent approval of monoclonal antibodies targeting CGRP or the CGRP receptor, the inhibition of CGRP-media…
View article: IC‐P‐142: [<sup>11</sup>C]MK‐6884 PET TRACER FOR M4 MUSCARINIC CHOLINERGIC RECEPTORS IN ALZHEIMER'S DISEASE: COMPARISON WITH [<sup>18</sup>F]FDG PET
IC‐P‐142: [<sup>11</sup>C]MK‐6884 PET TRACER FOR M4 MUSCARINIC CHOLINERGIC RECEPTORS IN ALZHEIMER'S DISEASE: COMPARISON WITH [<sup>18</sup>F]FDG PET Open
Cholinergic neuron loss has long been known to be a hallmark of AD. The largest class of therapeutic agents targets acetylcholinesterase in order to increase acetylcholine availability. In order to evaluate regional cholinergic tone in ind…
View article: IC‐P‐150: [C‐11]MK‐6884 PET: CHARACTERIZING BRAIN M4 RECEPTORS IN HEALTHY ELDERLY VOLUNTEERS AND ACETYLCHOLINESTERASE INHIBITORS‐TREATED AD PATIENTS
IC‐P‐150: [C‐11]MK‐6884 PET: CHARACTERIZING BRAIN M4 RECEPTORS IN HEALTHY ELDERLY VOLUNTEERS AND ACETYLCHOLINESTERASE INHIBITORS‐TREATED AD PATIENTS Open
The M4 muscarinic cholinergic receptor may play important roles in the pathophysiology and treatment of Alzheimer's disease (AD). This study aimed to assess the utility of [11C]MK-6884, a novel PET radiotracer targeting the M4 allosteric m…
View article: Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with <sup>18</sup>F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles
Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with <sup>18</sup>F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles Open
18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary tangles (NFTs). Plasma kinetics, brain uptake, and preliminary qu…
View article: [IC‐P‐207]: IN VITRO BINDING STUDIES TO EVALUATE THE NFT‐SPECIFICITY OF [<sup>3</sup>H]MK‐6240 AND [<sup>3</sup>H]AV‐1451 BINDING IN SUBCORTICAL REGIONS OF THE HUMAN AD BRAIN
[IC‐P‐207]: IN VITRO BINDING STUDIES TO EVALUATE THE NFT‐SPECIFICITY OF [<sup>3</sup>H]MK‐6240 AND [<sup>3</sup>H]AV‐1451 BINDING IN SUBCORTICAL REGIONS OF THE HUMAN AD BRAIN Open
[18F]MK-6240 is a promising PET tracer for the in vivo quantification of NFTs in Alzheimer's Disease (AD) patients1, 2. In clinical studies, [18F]MK-6240 shows high levels of retention in brain regions expected to contain NFT pathology in …
View article: Preclinical Characterization of<sup>18</sup>F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles
Preclinical Characterization of<sup>18</sup>F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles Open
18F-MK-6240 is a promising PET tracer for the in vivo quantification of NFTs in AD patients.